US EditionRFK Jr.’s CDC vaccine panel backs Merck RSV shot for infants
UNITED STATES, JUN 26 – The Advisory Committee on Immunization Practices voted 5-2 to recommend Merck's Enflonsia shot, which reduces RSV-related hospitalizations in infants by over 84%, as a new preventive option.
- On Wednesday, the newly reconstituted Advisory Committee on Immunization Practices voted 5-2 to recommend Merck's newly approved antibody, clesrovimab, for infant protection against respiratory syncytial virus.
- This vote came after the U.S. health official in charge replaced the previous 17-member advisory panel with a smaller seven-member group that includes several individuals known for vaccine skepticism, sparking controversy earlier this month.
- The committee also discussed thimerosal, a mercury-based preservative falsely linked to autism by antivaccine groups, including a presentation by Lyn Redwood, former president of Children's Health Defense, founded by Kennedy.
- Dr. Retsef Levi, a new appointee, raised safety concerns about antibody trials before the vote, but Dr. Cody Meissner called the results a "spectacular accomplishment" with broad public health impact.
- Chrissie Juliano, executive director of a national group representing large urban health departments, cautioned that politically motivated changes by ACIP could threaten the affordability and availability of vaccines for millions, highlighting the critical importance of maintaining sound immunization policies.
96 Articles
96 Articles
Respiratory syncytial virus entry and how to block it
Respiratory syncytial virus (RSV) is a leading cause of lower respiratory tract disease in young children and elderly people. Although the virus was isolated in 1955, an effective RSV vaccine has not been developed, and the only licensed intervention is passive immunoprophylaxis of high-risk infants with a humanized monoclonal antibody. During the past 5 years, however, there has been substantial progress in our understanding of the structure an…
This day Jorge Vilches, head of the Department of Epidemiology, and Valentina Pino, coordinator of the Winter Campaign of the Ministry of Health, announced a new Respiratory Virus Report, corresponding to the epidemiological week 25 -from June 15 to 21-. According to the authorities, during this period the positivity of the samples reached 43.5%, a figure discreetly lower than the one recorded the previous week. “This is 0.2% less regarding the …
RFK Jr.'s vaccine committee advises Merck's RSV shot for babies
(NewsNation) — Health and Human Services Secretary Robert F. Kennedy Jr.'s vaccine committee on Thursday voted to recommend a shot that protects babies against RSV, reports said. The shot, called Enflonsia, is made by Merck. Enflonsia is a preventive, long-acting monoclonal antibody designed to provide rapid protection through five months with the same dose regardless of weight. It is the second RSV monoclonal antibody of its kind on the market.…
Kennedy's Vaccine Panel Backs New RSV Shot
The first vote of Robert F. Kennedy Jr.'s new vaccine panel ended up being a surprising one, reports USA Today . The panel, which includes known vaccine critics , gave the green light to a new shot to protect infants from respiratory syncytial virus (RSV). Though two members disagreed, the Advisory...
A medical panel appointed by Health Secretary Robert F. Kennedy Jr. voted this Thursday for a new anti-RSV antibody treatment, a common respiratory disease that is the main cause of hospitalization of babies in the country.Read more]]>
Coverage Details
Bias Distribution
- 69% of the sources are Center
Factuality
To view factuality data please Upgrade to Premium
